Analysts at Cantor Fitzgerald initiated Novo Nordisk (NYSE:NVO) with an Overweight rating and a $120 per share price target in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback